LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 565

Search options

  1. Article ; Online: V. RESULTS-INDIVIDUAL DIFFERENCE FACTORS IN SPATIAL AND MATHEMATICAL SKILLS.

    Verdine, Brian N / Golinkoff, Roberta Michnick / Hirsh-Pasek, Kathy / Newcombe, Nora S

    Monographs of the Society for Research in Child Development

    2017  Volume 82, Issue 1, Page(s) 81–88

    MeSH term(s) Aptitude ; Aptitude Tests ; Child, Preschool ; Humans ; Individuality ; Mathematics ; Motor Skills/physiology ; Sex Factors ; Social Class ; Spatial Navigation
    Language English
    Publishing date 2017-02-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 414392-9
    ISSN 1540-5834 ; 0037-976X
    ISSN (online) 1540-5834
    ISSN 0037-976X
    DOI 10.1111/mono.12284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 300: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: Turning

    Hirsh, Vera

    Therapeutic advances in medical oncology

    2018  Volume 10, Page(s) 1758834017753338

    Abstract: Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available for the management ... ...

    Abstract Four epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib, gefitinib, afatinib and osimertinib, are currently available for the management of
    Language English
    Publishing date 2018-01-22
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2503443-1
    ISSN 1758-8359 ; 1758-8340
    ISSN (online) 1758-8359
    ISSN 1758-8340
    DOI 10.1177/1758834017753338
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.

    Hirsh, Vera

    OncoTargets and therapy

    2017  Volume 10, Page(s) 2513–2526

    Abstract: Until recently, few treatment options existed for the treatment of squamous cell carcinoma (SqCC) of the lung, especially in the second-line setting following platinum-based chemotherapy. Accordingly, outcomes in this subtype of non-small-cell lung ... ...

    Abstract Until recently, few treatment options existed for the treatment of squamous cell carcinoma (SqCC) of the lung, especially in the second-line setting following platinum-based chemotherapy. Accordingly, outcomes in this subtype of non-small-cell lung cancer (NSCLC) were generally poor. In this context, the recent availability of the checkpoint inhibitors nivolumab and pembrolizumab, the anti-VEGFR2 antibody ramucirumab (combined with docetaxel), and the ErbB-family blocker afatinib for the treatment of relapsed/refractory SqCC of the lung represent major advances. However, the rapid expansion of the treatment armamentarium invites many questions regarding optimal treatment choice and sequence in individual patients. This review focuses on the biologic rationale and clinical evidence to support the use of afatinib in this treatment setting, highlighting the prominent role of the ErbB-signaling cascade in SqCC tumors. The seminal Phase III LUX-Lung 8 study, on which the approval of afatinib is based, is discussed and contextualized with the emergence of immunotherapies. Finally, criteria are explored that might drive physicians' treatment decisions when considering the use of afatinib based on individual patient characteristics. Other ongoing developments in the treatment of SqCC of the lung that will lead to further options and welcome improvements in the management of this difficult-to-treat disease are summarized.
    Language English
    Publishing date 2017-05-11
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2495130-4
    ISSN 1178-6930
    ISSN 1178-6930
    DOI 10.2147/OTT.S104177
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: New developments in the treatment of advanced squamous cell lung cancer

    Hirsh V

    OncoTargets and Therapy, Vol Volume 10, Pp 2513-

    focus on afatinib

    2017  Volume 2526

    Abstract: Vera Hirsh McGill Department of Oncology, Royal Victoria Hospital, Montreal, QC, Canada Abstract ...

    Abstract Vera Hirsh McGill Department of Oncology, Royal Victoria Hospital, Montreal, QC, Canada Abstract: Until recently, few treatment options existed for the treatment of squamous cell carcinoma (SqCC) of the lung, especially in the second-line setting following platinum-based chemotherapy. Accordingly, outcomes in this subtype of non-small-cell lung cancer (NSCLC) were generally poor. In this context, the recent availability of the checkpoint inhibitors nivolumab and pembrolizumab, the anti-VEGFR2 antibody ramucirumab (combined with docetaxel), and the ErbB-family blocker afatinib for the treatment of relapsed/refractory SqCC of the lung represent major advances. However, the rapid expansion of the treatment armamentarium invites many questions regarding optimal treatment choice and sequence in individual patients. This review focuses on the biologic rationale and clinical evidence to support the use of afatinib in this treatment setting, highlighting the prominent role of the ErbB-signaling cascade in SqCC tumors. The seminal Phase III LUX-Lung 8 study, on which the approval of afatinib is based, is discussed and contextualized with the emergence of immunotherapies. Finally, criteria are explored that might drive physicians’ treatment decisions when considering the use of afatinib based on individual patient characteristics. Other ongoing developments in the treatment of SqCC of the lung that will lead to further options and welcome improvements in the management of this difficult-to-treat disease are summarized.Keywords: squamous cell carcinoma of the lung, afatinib, LUX-Lung 8, EGFR, ErbB
    Keywords squamous cell carcinoma of the lung ; afatinib ; LUX-Lung 8 ; EGFR ; ErbB ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282 ; Internal medicine ; RC31-1245 ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2017-05-01T00:00:00Z
    Publisher Dove Medical Press
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: FRAIL-AF Study: More Bleeding With DOACs Compared With VKAs in Patients With Frailty?

    Godoy, Alejandro / Chan, Noel C / Bhagirath, Vinai / Eikelboom, John W / Hirsh, Jack

    The Canadian journal of cardiology

    2024  

    Language English
    Publishing date 2024-01-02
    Publishing country England
    Document type Editorial
    ZDB-ID 632813-1
    ISSN 1916-7075 ; 0828-282X
    ISSN (online) 1916-7075
    ISSN 0828-282X
    DOI 10.1016/j.cjca.2023.12.030
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2150: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: Suspension of privileges to perform cardiovascular surgery. Giannelli v. St. Vincent's Hospital and Medical Center of New York.

    Hirsh, B D

    The Journal of cardiovascular management : the official journal of the American College of Cardiovascular Administrators

    1998  Volume 6, Issue 1, Page(s) 16–17

    MeSH term(s) Cardiac Surgical Procedures/mortality ; Cardiac Surgical Procedures/standards ; Cardiology Service, Hospital/legislation & jurisprudence ; Cardiology Service, Hospital/standards ; Humans ; Liability, Legal ; Medical Staff Privileges/legislation & jurisprudence ; New York
    Language English
    Publishing date 1998-07-21
    Publishing country United States
    Document type Legal Case
    ISSN 1053-5330
    ISSN 1053-5330
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: Jury verdict of $6.875 million in punitive damages for wrongful death affirmed by Alabama Supreme Court. Atkins v. Lee.

    Hirsh, B D

    The Journal of cardiovascular management : the official journal of the American College of Cardiovascular Administrators

    1998  Volume 6, Issue 1, Page(s) 11, 15–6

    MeSH term(s) Alabama ; Cardiac Catheterization/standards ; Cardiology Service, Hospital/legislation & jurisprudence ; Child, Preschool ; Credentialing/legislation & jurisprudence ; Death, Sudden, Cardiac ; Homicide/legislation & jurisprudence ; Humans ; Internship and Residency/legislation & jurisprudence ; Liability, Legal ; Male ; Malpractice/legislation & jurisprudence ; Nursing Staff, Hospital/legislation & jurisprudence
    Language English
    Publishing date 1998-07-21
    Publishing country United States
    Document type Legal Case
    ISSN 1053-5330
    ISSN 1053-5330
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article: Orbital Osteomyelitis and Periorbital Abscess Due to Coccidioidomycosis Following Trauma.

    Hayashi, Garrick / Pardo, Natalie / Hirsh, Nurit M / Vijayan, Vini

    Cureus

    2023  Volume 15, Issue 10, Page(s) e46586

    Abstract: Ocular involvement due ... ...

    Abstract Ocular involvement due to
    Language English
    Publishing date 2023-10-06
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2747273-5
    ISSN 2168-8184
    ISSN 2168-8184
    DOI 10.7759/cureus.46586
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine.

    Hirsh, Vera

    Frontiers in oncology

    2015  Volume 5, Page(s) 20

    Language English
    Publishing date 2015-02-03
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2015.00020
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib.

    Hirsh, Vera

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

    2015  Volume 29, Issue 3, Page(s) 167–183

    Abstract: First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with ... ...

    Abstract First-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, represented an important addition to the treatment armamentarium for non-small-cell lung cancer (NSCLC) patients with activating EGFR mutations. However, all patients inevitably develop acquired resistance to these agents, primarily due to secondary EGFR mutations, molecular aberrations affecting other signaling pathways, or transformation to small-cell histology. It was hypothesized that development of second-generation TKIs with broader inhibitory profiles could confer longer-lasting clinical activity and overcome acquired resistance to first-generation inhibitors. Here, we review the development of afatinib, an irreversible ErbB family blocker that potently inhibits signaling of all homodimers and heterodimers formed by the EGFR, human epidermal growth factor receptor (HER)-2, HER3, and HER4 receptors. In two phase III trials in patients with EGFR mutation-positive NSCLC, first-line afatinib significantly improved progression-free survival (PFS) and health-related quality of life versus standard-of-care chemotherapy. Moreover, in preplanned sub-analyses, afatinib significantly improved overall survival in patients harboring EGFR Del19 mutations. Afatinib has also demonstrated clinical activity in NSCLC patients who had progressed on erlotinib/gefitinib, particularly when combined with cetuximab, and offers 'treatment beyond progression' benefit when combined with paclitaxel versus chemotherapy alone. Furthermore, a recent phase III study demonstrated that PFS was significantly improved with afatinib versus erlotinib for the second-line treatment of patients with squamous cell carcinoma of the lung. The activity of afatinib in both first-line and relapsed/refractory settings may reflect its ability to irreversibly inhibit all ErbB family members. Afatinib has a well-defined safety profile with characteristic gastrointestinal (diarrhea, stomatitis) and cutaneous (rash/acne) adverse events.
    MeSH term(s) Afatinib ; Antineoplastic Agents/pharmacology ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Clinical Trials, Phase III as Topic ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Protein Kinase Inhibitors/pharmacology ; Quinazolines/pharmacology ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Protein Kinase Inhibitors ; Quinazolines ; Afatinib (41UD74L59M) ; EGFR protein, human (EC 2.7.10.1) ; ErbB Receptors (EC 2.7.10.1)
    Language English
    Publishing date 2015-06-27
    Publishing country New Zealand
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 1364202-9
    ISSN 1179-190X ; 1173-8804
    ISSN (online) 1179-190X
    ISSN 1173-8804
    DOI 10.1007/s40259-015-0130-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4112: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top